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 Context: Objective measurement of prenatal alcohol exposure (PAE) is essential for 
identifying children at risk of adverse outcomes, including fetal alcohol spectrum disorders. 
Biomarkers have been advocated for use in universal screening programs but their validity 
has not been comprehensively evaluated.  
 
Objective: To systematically review the validity of objective measures of PAE.   
 
Data Sources: Thirteen electronic databases and supplementary sources were searched for 
studies published between January 1990 and October 2015.  
 
Study Selection: Eligible studies were those that evaluated the diagnostic accuracy of 
objective measures of PAE. 
 
Data Extraction: Three reviewers independently verified study inclusion, quality 
assessments and extracted data. 
 
Results: Twelve studies met inclusion criteria. Test performance varied widely across studies 
of maternal blood (four studies; sensitivity 0% to 100%, specificity 79% to 100%), maternal 
hair (two studies; sensitivity 19% to 87%, specificity 56% to 86%) maternal urine (two 
studies; sensitivity 5% to 15%, specificity 97% to 100%), and biomarker test batteries (three 
studies; sensitivity 22% to 50%, specificity 56% to 97%). Tests of the total concentration of 
four fatty acid ethyl esters (in meconium - two studies, or placenta - one study) demonstrated 
high sensitivity (82% to 100%); however, specificity was variable (13% to 98%). 
 
Limitations: Risk of bias was high due to self-report reference standards and selective 
outcome reporting.  
 
Conclusions: Current evidence is insufficient to support the use of objective measures of 
prenatal alcohol exposure in practice. Biomarkers in meconium and placenta tissue may be 
the most promising candidates for further large-scale population-based research. 
 
 
 
  
 Up to 80% of women consume some level of alcohol while pregnant.1,2 Most drink at low 
levels and reduce their intake throughout pregnancy. However, up to 45% may binge drink in 
the first trimester and up to 6% continue to drink heavily.1 Prenatal alcohol exposure (PAE) is 
associated with a range of adverse perinatal and long-term outcomes including spontaneous 
abortion, preterm delivery and cognitive impairment.3-8 
Heavy fetal alcohol exposure is the most likely to lead to detrimental outcomes, including 
fetal alcohol spectrum disorders. The estimated prevalence of FASD is 3% to 5% within the 
general population in North America and Europe, and up to 26% in South Africa, making it 
one of the leading preventable causes of developmental disability worldwide.9,10  
Reviews of the effects of low to moderate PAE on short- and long-term developmental 
outcomes are inconclusive,11-13 and debate continues as to whether it is possible to identify a 
safe threshold for drinking in pregnancy.14,15 Observed effects of low to moderate PAE on 
childhood cognitive and behavioural outcomes range from evidence of harm,16-18 to null 
findings,19-22 to evidence of benefit.23-25 Studies of the effects of low to moderate PAE on 
birth outcomes and child growth trajectories are also inconsistent.2,26-31 Discrepancies in 
findings are likely due to measurement error and residual confounding owing to the 
socioeconomic patterning of prenatal alcohol use.16,32,33  
Inconsistencies in the evidence base are reflected in international guidelines for drinking in 
pregnancy. Most countries in North America, Europe and Australasia endorse a clear 
abstinence message.34 Current UK guidelines are controversial. The National Institute for 
Health and Care Excellence (NICE) recommend abstinence in the first trimester followed by 
no more than one to two units once or twice a week.35 However, in January 2016 the UK 
Chief Medical Officer issued new guidance stating that women should avoid alcohol 
throughout pregnancy.36  
 Self-report measures are the most common method for assessing PAE and include survey 
methods and standardised questionnaires.37-39 Although widely used, self-report measures are 
likely to underestimate true levels of alcohol consumption for reasons including social stigma 
and difficulties in recalling drinking behaviour.40-42 Objective measures are needed to help 
researchers ascertain the true prevalence of PAE, and to better understand the effects of low 
to moderate exposure. For clinicians, objective measures of PAE could support FASD 
diagnosis and guide efforts to prevent alcohol-related harm.43-48 
Biomarkers have received increasing attention as objective measures of PAE.49-54 Alcohol 
biomarkers can be found in a range of biological matrices including maternal blood, sweat, 
urine, oral fluid and hair; newborn blood, urine, hair and meconium; and in maternal-fetal 
matrices such as the placenta.51 Direct biomarkers include ethanol itself or the products of 
ethanol metabolism. Indirect markers are those that signal alcohol-induced pathology, 
following chronic alcohol use.52  
Some groups have advocated the use of biomarkers of PAE within universal screening 
programs.55 For example, meconium testing features as a recommended method within the 
Canadian FASD National Screening Tool Kit.56 However, the evidence for the diagnostic 
accuracy of biomarkers has not been comprehensively evaluated. In this context, we carried 
out a systematic review of the diagnostic accuracy of objective measures of PAE.   
Methods 
We followed the Cochrane Collaboration guidelines for systematic reviews of diagnostic test 
accuracy,57 the Standards for the Reporting of Diagnostic Accuracy Studies (STARD),58 and 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement (see Supplementary File 1 for PRISMA checklist).59 The full protocol is available 
 from the PROSPERO international prospective register of systematic reviews 
(www.crd.york.ac.uk; record number CRD42014015420).  
Search strategy  
Figure 1 presents an overview of the search strategy including sources of literature. We 
searched 13 electronic databases, including sources of grey literature, from January 1990 to 
August 2015 for original articles using combinations of terms related to objective measures 
and diagnostic accuracy and prenatal alcohol exposure. Searches were limited to 
publications from January 1990 onwards to increase precision. A scoping exercise of existing 
non-systematic reviews revealed no relevant articles prior to 1990.50,52,60-62 Full details of the 
search strategy for Medline is available in Supplementary File 2. This search string was 
translated for use in all other databases. Supplementary sources were searched for articles 
published between November 2012 and October 2015. We contacted authors to request 
further information about missing or conflicting data.  
Inclusion/exclusion criteria 
Eligible studies were randomised screening studies and diagnostic cross-sectional, cohort, 
and case-control studies of pregnant and/or postpartum women and/or neonates that 
investigated the performance of any objective measure of PAE in comparison to any 
reference standard.  
We excluded conference abstracts, studies with missing outcome data, and animal studies. 
Non-English language publications were excluded due to a lack of funding for translation 
costs.  
Study selection 
 After removing duplicates, CM screened the search records against pre-determined inclusion 
criteria and excluded ineligible studies based on the title or abstract. Full text versions were 
obtained to determine the inclusion of potentially relevant studies. A random selection of 
10% of these studies were independently assessed for eligibility by two other reviewers (LH 
and SP). The level of agreement for inclusion decisions was 100%.  
Data extraction 
All data were extracted by CM into a standardised electronic form, designed based on the 
Guidelines International Network (GIN) template for diagnostic studies and STARD.58,63 SP 
or LH independently repeated data extraction to ensure accuracy. We extracted information 
about study design, participant, index and reference test characteristics, and diagnostic 
accuracy outcomes. Alcohol data were classified according to the United States National 
Institute on Alcohol Abuse and Alcoholism criteria for the general population in which one 
standard drink is equivalent to 0.6 oz. or 14 g of ethanol and light drinking is equivalent to < 
3 drinks per week, moderate drinking 3 to 7 drinks per week, and heavy drinking > 7 drinks 
per week or a binge pattern of ≥ 4 drinks per occasion.64  
Quality assessment  
We used a modified version of the Quality Assessment of Diagnostic Accuracy Studies tool 
(QUADAS-2) to assess the methodological quality of included studies.65 QUADAS-2 was 
tailored to address specific areas of relevance for this review, based on guidance from the 
Cochrane Collaboration (see Supplementary File 3 for quality coding criteria).66,67 
Methodological quality was independently assessed by two members of the review team (CM 
and SP or LH) and referred to a third member of the team to resolve any disagreements in 
risk of bias decisions.  
 Analysis and data synthesis 
A minimum of four studies per test are required for meta-analyses of diagnostic accuracy data 
within STATA using the recommended Rutter and Gatsonis HSROC model.68,69 Due to the 
diverse nature of the data, which represented a variety of measures and assay methods across 
a range of matrices, none of the test categories had a sufficient number of studies to facilitate 
meta-analysis. Therefore, we conducted a narrative synthesis of the data. Sensitivity, 
specificity, predictive values, and likelihood ratios were the key diagnostic accuracy 
outcomes.  
Diagnostic accuracy data were entered into Review Manager (RevMan).70 Where necessary, 
the RevMan calculator to was used to derive diagnostic summary statistics from true positive, 
true negative, false positive and false negative values and vice-versa. If there were 
insufficient data to enable the use of the RevMan calculator, we used R software71 to conduct 
an exhaustive search of all possible 2x2 tables that were consistent with the data supplied in 
the primary study. Confidence intervals were generated automatically using the exact 
binomial method72 in RevMan for sensitivity and specificity values and with the MedCalc 
online calculator73 for predictive values. Confidence intervals for likelihood ratios were 
generated using the method described by Koopman.74  
Many studies reported a range of diagnostic accuracy values according to characteristics such 
as positivity cut-off and period of measurement. In order to aid presentation of findings, we 
report only the highest values of both sensitivity and specificity per study within the summary 
of results.  
Ethics committee approval 
Ethical approval was not required as the study used secondary data. 
 Results 
Characteristics of included studies 
From 4278 search records, 12 studies, including 1614 unique participants, met eligibility 
criteria.75-86 Figure 1 depicts the study selection process and Table 1 presents characteristics 
of included studies. 
Studies included data on participants from the USA (5),75,77,82,84,85 Korea (2),80,81 Spain (1),86 
South Africa (1),76 and Finland (1)83, and combined data from the USA and Jordan (1),78 and 
Canada and Israel (1).79 Diagnostic accuracy data were available for eight types of biomarker: 
carbohydrate deficient transferrin (CDT),75,83,85 ethyl sulphate (EtS),75,85 ethyl glucuronide 
(EtG),75,85,86 fatty acid ethyl esters (FAEEs),75-80,82,84 gamma glutamyltransferase 
(GGT),75,83,85 haemoglobin acetaldehyde adducts (Hb-Ach),83 mean corpuscular volume 
(MCV)83 and phosphatidylethanol (PEth),75,81,85 within six matrices: meconium,75-80,82 
placenta,84 maternal urine,75,85 maternal blood,75,81,83,85 maternal hair85,86 and infant blood.75 
Eight studies investigated tests of moderate to heavy prenatal alcohol 
consumption75,76,78,79,81,83-85 and nine recruited women from high-risk settings, such as 
substance misuse clinics.75-79,82-85 Eight of the eligible studies recruited pregnant women who 
reported abstinence from alcohol as a comparison group.75,77-82,85 Two of these studies 
included an additional control group of pregnant women from cultures that promote 
abstinence from alcohol.78,79 Three of the studies explored test performance for distinguishing 
between heavy drinkers and women with lower levels of prenatal alcohol 
consumption76,81,83,84 and one study did not report characteristics of the control group.86 
Methodological quality of included studies 
Results of the QUADAS-2 quality assessment are presented in Figures 2 and 3.  
 All but one of the studies used a self-report reference standard and had a high risk of bias for 
the reference standard domain.75-85 Self-report is known to be an imperfect reference standard 
for reasons previously discussed. The remaining study86 used meconium EtG as the reference 
standard. This study was considered to have an unclear risk of bias as the validity of 
meconium EtG has not been established and there is a lack of agreement about the optimal 
positivity threshold for this biomarker.87-89 Seven studies had a high risk of bias in the 
participant selection domain due to the use of diagnostic case-control designs,75-80,85 which 
may inflate accuracy estimates.90-92 Nine studies had a low risk of bias for uninterpretable 
results,75,76,78-83,86 withdrawals,75,76,78-81,83,85,86 differential verification,75-77,80,81,83-86 and partial 
verification.75,76,79-81,83-86 The risk of incorporation bias was high in one study as EtG was 
used to indicate alcohol exposure in both the reference standard and index test.86 
Seven studies had a low risk of bias for the detection window domain.75,77-80,83,86 Of these 
studies, two reported data for multiple index tests both with and without an appropriate 
window of detection.75,78 In order to reduce the risk of bias, data were excluded from one 
study that looked at the agreement between self-reported drinking in the first trimester and 
meconium testing,78 as meconium does not begin to accumulate until the second and third 
trimesters.60 We also excluded data from another study that compared self-reported PAE 
during the second trimester with postnatal tests of maternal EtG, EtS, GGT, CDT and PEth in 
dried infant blood spots due to the short detection window of these biomarkers.75 Of the 
remaining studies, two had an unclear risk of bias and three had a high risk of bias. Two of 
these studies76,82 were deemed to have a high risk of bias as the accuracy of meconium testing 
was verified against alcohol use across the whole of pregnancy, including the first trimester 
before meconium is generated. It was not possible to exclude first trimester data from our 
analysis due to the way findings were reported. One study,85 which collected maternal hair 
during pregnancy for EtG testing, was also considered to have a high risk of bias as the 
 specimen may have captured alcohol use prior to pregnancy due to the broad detection 
window of EtG within this matrix.  
Finally, selective outcome reporting introduced a high risk of bias in four studies.76-79 Of 
these studies, three measured multiple FAEEs in meconium but only reported diagnostic 
accuracy outcomes for a subset of these FAEEs.76-78 Two studies78,84 did not provide 
sufficient data to enable the use of the RevMan calculator to derive missing true positive, true 
negative, false positive and false negative values. Using the R simulation, we were able to 
produce data that replicated the sensitivity, sensitivity and predictive values reported in one 
of the studies,84 and generated values that approximated the published data in another study.78 
For the remaining study of meconium FAEEs,79 the positive predictive value reported in the 
study did not match the value suggested by the raw data (see Table 2 for further details). The 
study authors were unable to provide data to further explore this discrepancy. Finally, we 
were unable to replicate the published sensitivity and specificity values based on the true 
positive, true negative, false positive, and false negative values presented in one study of 
maternal hair testing.86 Following correspondence with the authors the correct sensitivity and 
specificity values were derived based on the raw values presented in the paper (see Table 5).  
Diagnostic accuracy findings 
Tables 2 - 7 present diagnostic accuracy outcomes with 95% confidence intervals.  
Meconium testing 
Meconium testing for FAEEs was the most commonly investigated index test and featured in 
seven studies.75-80,82 The diagnostic accuracy of FAEEs varied widely across studies (see 
Table 2). A measure of the total concentration of four FAEEs demonstrated the highest levels 
 of diagnostic accuracy overall, but there were a high number of false positives in one study75 
and specificity was inconsistent.75,79  
Placenta testing 
FAEEs were measured in placenta tissue in one study of premature deliveries.84 Sensitivity 
and specificity values were high, although 30% to 56% of positive test results were false 
positives (see Table 3).  
Blood testing 
Four studies investigated CDT, GGT, Hb-Ach, MCV and PEth75,81,83,85 within prenatal 
samples of maternal blood. Blood biomarkers generally demonstrated low sensitivity, 
although specificity was high (see Table 4). Likelihood ratios suggested that the accuracy of 
PEth testing improved as PAE increased from low to moderate to heavy. However, findings 
of high levels of sensitivity (100%) and specificity (96%) in one study of heavy PAE81 were 
not supported by two other studies in which sensitivity was 18% to 22%.75,85  
Hair testing 
Maternal hair was tested for EtG in two studies85,86 with contrasting findings (see Table 5). 
Neither of the studies demonstrated high levels of both sensitivity and specificity.  
Urine testing 
EtS and EtG in maternal urine had low sensitivity but high specificity in two studies75,85 (see 
Table 6).  
Test batteries 
 Three studies investigated the diagnostic accuracy of test batteries including combinations of 
different biomarkers across multiple matrices.75,83,85 Sensitivity was poor, while specificity 
was generally good (see Table 7). 
Discussion 
This systematic review demonstrates that the accuracy of biomarkers of PAE varies widely 
across studies. Tests of the total concentration of four FAEEs demonstrated the highest levels 
of sensitivity across studies. Sensitivity was 100% in two studies of meconium testing,75,79 
and 82% in one study of placenta testing.84 However, specificity was variable (13% to 98%). 
Positive likelihood ratios ranged from 1, suggesting little test utility, to 73. As a guide, 
positive likelihood ratios greater than 10 may indicate that a test is informative.93 Due to a 
small number of cases in these studies confidence intervals were wide, leading to imprecise 
estimates of diagnostic accuracy. Placenta testing was conducted with a sample of premature 
newborns.84 It is important to note that because alcohol is a risk factor for prematurity,94 the 
prevalence of PAE is likely to be higher within this sample than in the general population. 
Accordingly, positive predictive values from this study are likely to be higher than what 
would be expected within routine antenatal care.95  
There is no consensus as to what level of diagnostic accuracy is acceptable for objective 
measures of PAE. Many screening initiatives prioritise sensitivity over specificity and thus 
permit a high number of false positive results in order to maximise early detection of 
asymptomatic conditions.96 As early diagnosis and intervention are associated with improved 
outcomes for children with FASD43 it could be argued that a test with high sensitivity could 
be favoured over specificity in this context, as it may facilitate appropriate monitoring and 
follow-up among children with positive PAE screens. However, PAE is a highly emotive 
topic and false positive errors may lead to stigmatisation, unnecessary burden on healthcare 
 resources, and may even be used in legal proceedings against mothers.55,96-99 Conversely, 
false negative errors represent a missed opportunity to provide support to families affected by 
PAE.55 Many screening programmes are conducted in a tiered fashion with high sensitivity 
favoured over specificity in the initial phase. Second-tier screening using methods such as 
detailed maternal interviews and behavioural assessment of children with suspected PAE 
have been suggested as a strategy to reduce false positive results.55 However, these methods 
also have limitations. Information from maternal interview may be inaccurate, and the 
cognitive-behavioural profile associated with PAE is heterogeneous and may not be 
detectable until later in childhood, thus precluding the opportunity for early intervention. 
Given the implications of both types of diagnostic error, various authors have suggested that 
both high sensitivity and specificity are a prerequisite for the introduction of PAE 
screening.55,96,99  
Limitations of the evidence 
The methodological quality of studies included in this review was generally poor. Risk of 
bias was high due to the use of imperfect self-report reference standards, case-control 
diagnostic designs, and selective outcome reporting. Therefore, it is unclear whether the low 
diagnostic accuracy values of biomarkers explored in this review result from a true lack of 
test validity, or are simply an artefact of comparison with an imperfect reference standard. As 
self-report reference standards are known to underestimate true PAE it is possible that the 
biomarker index tests explored in this review correctly detected true PAE while the reference 
standard did not. This lack of agreement in classification would result in false positives and 
reduced specificity. However, it is also possible that the observed false positives were 
genuine. Incidental exposure to ethanol can occur through an individual’s diet, medications, 
mouthwash and hand sanitizer, although the extent to which incidental exposure influences 
 biomarker tests for PAE has not been fully established.100-104 It is unlikely that false negative 
results are due to the use of an imperfect reference standard as mothers are unlikely to report 
that they drank alcohol while pregnancy when they had not.105 Therefore, the low sensitivity 
values demonstrated by many studies in this review may be considered the most persuasive 
evidence against the validity of current objective measures of PAE. Some authors have 
proposed that apparent false negative errors may occur because self-report measures are 
better able to detect low levels of alcohol use than many of the objective measures, which 
typically detect moderate to heavy consumption. This raises the possibility that pregnant 
women who report drinking modest amounts of alcohol could be detected by the self-report 
reference standard but not the index test.106 This explanation is not likely to account for 
findings in the present review, however, as the majority of studies investigated moderate to 
heavy self-reported PAE.  
Case-control diagnostic designs may produce overestimates of diagnostic accuracy.90,92 
However, this form of bias is not likely to influence the conclusions of this review as most 
studies did not show high levels of accuracy despite the use of case-control diagnostic 
designs. It is, however, important to note that PAE prevalence is fixed by design in many of 
the studies included in this review due to the use of case-control methods and it is not 
possible to generalise predictive values from individual studies to settings with a different 
prevalence of PAE.93,95,107 
Finally, selective outcome reporting was common among studies and introduced a further 
risk of bias. As recommended by the STARD guidelines,58 we would urge authors to report 
reference and index test results in the form of absolute values to enable independent 
verification of findings. 
Limitations of the review 
 This study is the first systematic review of its kind and provides a rigorous evaluation of the 
evidence relating to the diagnostic accuracy of a range of objective measures of PAE. Our 
findings are broadly consistent with findings from existing non-systematic reviews, which 
suggest the need for improved objective measures of PAE.49,52,60 However, due to the diverse 
nature of the data and a limited number of studies per index test it was not possible to address 
some of the objectives listed in our original protocol. For example, we were not able to 
conduct the intended meta-analyses to answer questions about the relative impact of study 
characteristics on test accuracy. Our search strategy was comprehensive and covered a range 
of published and unpublished sources. It is possible, however, that some studies were missed 
as a result of excluding non-English language publications.  
As previously noted, participants were mainly recruited from high risk settings, such as 
substance misuse clinics. Therefore, findings have limited applicability to general population 
samples. Population-based studies of biomarkers of PAE are needed to inform universal 
screening strategies and to clarify the epidemiology of PAE and its developmental 
consequences in the short- and long-term. 
Implications 
Prenatal alcohol use is a challenging and emotive issue. Consequently, tests to detect prenatal 
alcohol exposure must be accurate, feasible, and acceptable to the population. These criteria 
are emphasised in the World Health Organisation and UK National Screening Committee 
guidelines for screening procedures.108,109 Our review demonstrates that the evidence base for 
the accuracy of current objective measures of PAE is not yet robust enough to support their 
use in routine care. More research is required to establish which method is most feasible and 
acceptable to stakeholders including clinicians, policy makers and families.96,97,110,111  
 Assay methods for the biomarkers included in this review were highly variable. This is likely 
to account for some of the observed heterogeneity in findings. Future work that aims to 
standardise procedures may provide a clearer picture of the performance of different 
biomarkers for PAE. Furthermore, positivity thresholds must be validated with general 
population samples. The 600 ng/g (2 nmol/g) cut-off for total concentration of four FAEEs 
was derived from a study comparing abstainers to women with alcoholism and, therefore, 
may not be suitable for determining PAE in the general population.79 
With the exception of hair testing, objective measures of PAE have a limited detection 
period, which does not span the whole of pregnancy (see Supplementary File 3). For many 
women, patterns of alcohol consumption change throughout pregnancy. Women are most 
likely to drink in the first trimester and then reduce their intake or abstain in later trimesters.1 
Risk of harm to the developing fetus is highest if a mother drinks heavily throughout 
pregnancy,112 however first trimester exposure poses a particular risk of physical 
abnormalities including dysmorphic facial features.113 Meconium testing only captures PAE 
late in the second and third trimesters of pregnancy and, therefore, may fail to identify a large 
proportion of babies at risk of alcohol-related harm.60 In addition, currently available 
biomarkers have insufficient sensitivity to detect low levels of PAE, which is the most 
prevalent pattern of consumption among pregnant women.1 An objective test which measures 
alcohol itself in breath, urine, or blood could detect low level use. However, because alcohol 
is only present in these matrices for a matter of hours, this form of test is difficult to 
implement in research or in practice.49,52 Due to the limitations of current biomarkers, authors 
have emphasised the need for novel biomarkers that can detect even low levels of alcohol use 
across the duration of pregnancy.49 
 Given the absence of a gold standard test, research attempting to validate objective measures 
of PAE may benefit from abandoning the classic diagnostic accuracy paradigm, in which 
validity is determined by agreement between the index test and reference standard. Instead, 
future research may benefit from using a clinical validation approach,114 in which a 
convergent body of evidence is used to increase confidence in the validity of a measure. 
Some studies have adopted this method to demonstrate the predictive validity of meconium 
testing. Prospective studies have reported a significant inverse relationship between levels of 
FAEEs in meconium and cognitive outcomes up to age 15.115,116 Such evidence lends support 
to the validity of FAEEs as markers of PAE, but require replication. Animal models may also 
be useful for the development of novel testing procedures for PAE.49,117,118 However, 
translation from animal studies to human populations is complicated by differences in alcohol 
exposure methods, gestation and alcohol metabolism. In summary, validation will rely on an 
ongoing body of research that produces convergent evidence to suggest that objective 
measures are meaningfully associated with PAE.114  
Conclusions 
Tests of the total concentration of FAEEs in meconium and placental tissue offer some 
promise as objective measures of PAE but findings are inconsistent, studies are small-scale 
and require replication. Therefore, we conclude that current evidence is insufficient to 
support the use of objective measures of PAE in practice. The poor performance of many of 
the measures evaluated in this review could be due to a true lack of diagnostic validity or a 
result of bias introduced by sub-optimal study design, most notably the absence of a gold 
standard for PAE. Further research that investigates test validity, acceptability, and feasibility 
within a large population-based sample is required to inform strategies for population-based 
screening and epidemiological research.   
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